Share via Print Currently, no federal agency tests the toxicity of new materials before they are allowed on the market. Food and Drug Administration banned the sale of baby bottles that contain bisphenol A BPAa compound frequently found in plastics. BPA is the starting material for making polycarbonate plastics. Any leftover BPA that is not consumed in the reaction used to make a plastic container can leach into its contents.
Allergic asthma[ edit ] Omalizumab is used to treat people with severe, persistent allergic asthma, uncontrollable with oral or injectable corticosteroids.
The allergic reaction is probably not due to the binding characteristics of the antibody drug, but to the protein nature of the antibody[ citation needed ].
The patients who use omalizumab are generally highly allergic. Thus, even though the drug is administered with the purpose to suppress allergy including anaphylactic reactionsit does not work immediately after injection. The data pooled in from the earlier phase I to phase III clinical trials showed a numeric imbalance in malignancies arising in omalizumab recipients 0.
The prespecified primary analysis assessed the incidence of primary malignancy in 32 randomized, double-blind, placebo-controlled RDBPC trials. In this analysis, there were 11, unique patients in all clinical trials 7, received omalizumab. Incidence rates Medical case studies on asthma 1, patient-years of observation time for omalizumab- and placebo-treated patients were 4.
Primary malignancies were of varying histologic type and occurred in a number of different organ systems; no cluster of histologies was identified. The study thus concluded that in this pooled analysis no association was observed between omalizumab treatment and risk of malignancy in RDBPC trials; the rate ratio was below unity.
The data suggest that a causal relationship between omalizumab therapy and malignancy is unlikely. The rationale for designing the anti-IgE therapeutic antibodies and the pharmacological mechanisms of anti-IgE therapy have been summarized in review articles by the inventor of the anti-IgE therapy, Tse Wen Chang, and his colleagues.
However, when IgE is bound to the receptor, the antigenic epitope on IgE to which omalizumab binds is sterically hindered by the receptor and is not accessible to omalizumab binding, thus averting the anaphylactic effects presumably unavoidable with an ordinary anti-IgE antibody.
Many investigators have identified or elucidated a host of pharmacological effects, which help bring down the inflammatory status in the omalizumab-treated patients.
Before the introduction of omalizumab, moderate to severe cases of asthma, regardless of their allergic or non-allergic nature, had been generally treated with corticosteroids and bronchodilators. Clinicians had not had persuasive reasons to dissect the role of IgE, or more precisely, its relative importance among various immune factors and pharmacological mediators, in the pathogenesis of asthma and various other allergic diseases and conditions.
The availability of omalizumab as a drug to intervene the IgE pathway has provided many clinical researchers the opportunities to examine the role of IgE in various allergic diseases and, in some cases, diseases that are not obviously considered as allergic diseases. In conjunction with achieving the practical goal to investigate the applicability of the anti-IgE therapy as a potential treatment for allergic diseases, the many corporate-sponsored clinical trials of TNX and omalizumab on asthma, allergic rhinitis, peanut allergy, chronic idiopathic urticaria, atopic dermatitis, and other allergic diseases, have helped define the role of IgE in the pathogenesis of these prevalent allergic diseases.
For example, the clinical trial results of omalizumab on asthma have unambiguously settled the long debate whether IgE plays a central role in the pathogenesis of asthma.
Numerous investigator-initiated case studies or small-scale pilot studies of omalizumab have been performed on various allergic diseases and several non-allergic diseases, especially inflammatory skin diseases.
These diseases include atopic dermatitis, various subtypes of physical urticaria solar, cold-induced, local heat-induced, or delayed pressure-inducedand a spectrum of relatively less prevalent allergic or non-allergic diseases or conditions, such as allergic bronchopulmonary aspergillosis cutaneous or systemic mastocytosisbee venom sensitivity anaphylaxis idiopathic anaphylaxis, eosinophil-associated gastrointestinal disorder, bullous pemphigoid interstitial cystitis nasal polyps, and idiopathic angiodema.
The results of some of these case studies and pilot studies have subsequently persuaded the drug companies marketing omalizumab to carry out larger-scale trials on some of the diseases. Roles in non-allergic diseases[ edit ] Several groups have reported clinical trial results that omalizumab may be effective in patients with non-allergic asthma.
For example, a portion of the cases of chronic idiopathic urticaria   and all cases of bullous pemphigoid  are clearly autoimmune diseases.
For the remaining cases of chronic idiopathic urticaria and those of the different subtypes of physical urticaria, the internal abnormalities leading to the disease manifestation have not been identified.
Notwithstanding these developments, it is apparent that many of those diseases involve inflammatory reactions in the skin and the activation of mast cells. An increasing series of papers have shown that IgE potentiates the activities of mast cells  and omalizumab can function as a mast cell-stabilizing agent,  rendering these inflammatory cells to be less active.Search Harvard Health Publishing.
What can we help you find?
Enter search terms and tap the Search button. Both articles and products will be searched. Case Studies on Updates in Allergy and Asthma Susan Raschal, DO Covenant Allergy and Asthma Care. Case 1. She has no significant past medical history.
She takes no medications. She is an avid hiker. She has never had a similar reaction. Defective Drug attorneys - Parker Waichman LLP, dedicated to defending Defective Drug victims.
Contact us at for FREE case evaluation.
SAMPLE CASE STUDY BASED ON ACTUAL PATIENT International Academy of Medical Acupuncture Case Studies Case Number: 14 Patient Initials: JSW Initial Date of Patient Consult/Treatment: January 13th, In summary, the medical diagnosis of “Adult-Onset Asthma” was given.
The Agency for Toxic Substances and Disease Registry (ATSDR) is an agency of the U.S. Department of Health and Human Services charged under the Superfund Act to assess the presence and nature of health hazards at specific Superfund sites and to help prevent or reduce further exposure and the illnesses that result from such exposures.
Interactive Medical Cases Case — A 64 cells and many of their secreted products have long been thought to contribute to the pathologic processes underlying asthma,1,2 but no.